Most Read Articles
20 Aug 2015
Intralesional vitamin D3 injection may be an effective treatment alternative for plantar warts as demonstrated in a study.
06 May 2015

Antigenic seniority and cross-reactivity are important determinants of host immunity against seasonal influenza viruses, according to a recent study.


Pank Jit Sin, 01 Dec 2013

Shingles, which presents as a painful and severe rash, can lead to serious complications among the elderly.

06 May 2015

Researchers have developed and validated a novel score for predicting the five-year risk of chronic kidney disease (CKD) in patients with HIV infection.


Tedizolid may be effective in MRSA-associated skin infections

16 Mar 2017

The novel oxazolidinone tedizolid appears to be clinically superior to vancomycin and comparable with other monotherapy drugs in treating serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), according to a systematic review and network meta-analysis.

Tedizolid has been shown in phase III noninferiority trials to have a favourable tolerability profile and is as effective as linezolid against a wide range of Gram-positive pathogens in the treatment of acute bacterial skin and skin structure infections (ABSSSI). [Antimicrob Agents Chemother 2015;59:864-71]

A total of 10 databases were searched for eligible studies consisting of randomized clinical trials (RCTs) published in English that investigated the efficacy of tedizolid or other established antimicrobials (namely, vancomycin, linezolid, daptomycin, teicoplanin, tigecycline, ceftaroline or telavancin) as monotherapy in adults with suspected or documented MRSA-ABSSSI, or complicated skin and skin structure infections (cSSSI).

Outcome measures included clinical response rate at end of therapy (EOT), post-therapy evaluation (PTE) or test-of-cure (TOC) assessment as well as serious adverse events (AEs) leading to discontinuation of treatment.

Of the 3,618 identified records, 15 RCTs were included for analysis. Tedizolid was shown to be superior in terms of clinical response at EOT (odds ratio [OR], 1.7) and had higher odds of clinical response at PTE or TOC (OR, 1.6) compared with vancomycin, but not with other comparators. No difference was observed among all treatments for discontinuation due to AEs.

“These findings suggest that tedizolid provides an alternative option for the management of serious skin infections caused by suspected or documented MRSA,” said researchers, adding that caution must be observed in interpreting the study results.
Editor's Recommendations
Most Read Articles
20 Aug 2015
Intralesional vitamin D3 injection may be an effective treatment alternative for plantar warts as demonstrated in a study.
06 May 2015

Antigenic seniority and cross-reactivity are important determinants of host immunity against seasonal influenza viruses, according to a recent study.


Pank Jit Sin, 01 Dec 2013

Shingles, which presents as a painful and severe rash, can lead to serious complications among the elderly.

06 May 2015

Researchers have developed and validated a novel score for predicting the five-year risk of chronic kidney disease (CKD) in patients with HIV infection.